LOGIN  |  REGISTER
Cue Biopharma
Recursion

Schrödinger to Participate in Upcoming Investor Conferences

February 20, 2024 | Last Trade: US$17.56 0.14 0.80

NEW YORK / Feb 20, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in March:

  • TD Cowen 44th Annual Health Care Conference: Fireside chat on Tuesday, March 5, 2024 at 10:30 a.m. ET.
  • Leerink Partners Global Biopharma Conference: Fireside chat on Monday, March 11, 2024 at 12:40 p.m. E.T.
  • KeyBanc Life Sciences & MedTech Forum (Virtual): Fireside chat on Wednesday, March 20, 2024 at 10:30 a.m. E.T.

The live discussions can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page